Werewolf Therapeutics (NASDAQ:HOWL) Given New $3.00 Price Target at JMP Securities

Werewolf Therapeutics (NASDAQ:HOWL) had its target price trimmed by JMP Securities from $4.00 to $3.00 in a research report released on Thursday,Benzinga reports. The firm currently has a market outperform rating on the stock.

Separately, Wedbush reduced their target price on Werewolf Therapeutics from $8.00 to $6.00 and set an “outperform” rating on the stock in a research report on Friday, May 9th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $8.00.

Werewolf Therapeutics Trading Up 3.2%

Shares of NASDAQ:HOWL opened at $1.28 on Thursday. The business’s 50-day moving average is $1.23 and its 200 day moving average is $1.15. Werewolf Therapeutics has a 1 year low of $0.5950 and a 1 year high of $4.18. The firm has a market capitalization of $58.53 million, a P/E ratio of -0.78 and a beta of 0.63. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.30 and a quick ratio of 8.09.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10. On average, research analysts predict that Werewolf Therapeutics will post -1.56 earnings per share for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

Large investors have recently added to or reduced their stakes in the company. D. E. Shaw & Co. Inc. purchased a new stake in Werewolf Therapeutics during the 4th quarter valued at about $26,000. Quadrature Capital Ltd purchased a new stake in Werewolf Therapeutics during the 2nd quarter valued at about $28,000. Vontobel Holding Ltd. purchased a new stake in Werewolf Therapeutics during the 1st quarter valued at about $34,000. Qube Research & Technologies Ltd purchased a new stake in Werewolf Therapeutics during the 2nd quarter valued at about $48,000. Finally, Nuveen LLC purchased a new stake in Werewolf Therapeutics during the 1st quarter valued at about $71,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.